{"organizations": [], "uuid": "79cae889fc9f40027fff98717a2f0bc2031b268b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.morningstar.com", "main_image": "", "site_section": "http://news.morningstar.com/all/dow-jones/technology.aspx", "section_title": "News Archive: Technology", "url": "http://news.morningstar.com/all/dow-jones/technology/2015100511359/fda-approves-alkermes-schizophrenia-treatment-aristada.aspx", "country": "US", "title": "FDA Approves Alkermes' Schizophrenia Treatment Aristada", "performance_score": 0, "site": "morningstar.com", "participants_count": 1, "title_full": "FDA Approves Alkermes' Schizophrenia Treatment Aristada", "spam_score": 0.0, "site_type": "news", "published": "2015-10-05T03:00:00.000+03:00", "replies_count": 0, "uuid": "79cae889fc9f40027fff98717a2f0bc2031b268b"}, "author": "morningstar.com", "url": "http://news.morningstar.com/all/dow-jones/technology/2015100511359/fda-approves-alkermes-schizophrenia-treatment-aristada.aspx", "ord_in_thread": 0, "title": "FDA Approves Alkermes' Schizophrenia Treatment Aristada", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "By Maria Armental\nThe Food and Drug Administration on Monday approved Alkermes PLC's schizophrenia treatment clearing the way for the Dublin-based bio pharmaceutical company to start selling the drug.\nAristada, or aripiprazole lauroxil, will be available as a once-monthly and six-week injection, is a generic version of Abilify.\nIn April, the FDA approved four other generics of Otsuka Pharmaceutical Co.'s best-selling drug Abilify by Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceuticals Industries Ltd. and Torrent Pharmaceuticals Ltd.\nIn 2014, the last full year in which Bristol-Myers Squibb Co. had exclusive rights to sell Abilify in the U.S., it reported $2.02 billion in sales of the drug. Bristol-Myers' exclusive rights ended in April along with Otsuka's Abilify market exclusivity.\nSchizophrenia is a chronic, disabling brain disorder that affects about 1% of the U.S. population, according to the National Institute of Mental Health.\nAristada is not approved to treat patients with dementia-related psychosis. The most common adverse reactions in a clinical trial were insomnia, headaches and akathisia, a form of inner restlessness.\nCompany officials have scheduled a conference call with analysts on Tuesday at 7:30 a.m. ET.\nShares, up 2.1% this year, rose 6% in late trading to $63.50.\nWrite to Maria Armental at maria.armental@wsj.com\n 05, 2015 20:51 ET (00:51 ", "external_links": ["http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif", "http://s7.addthis.com/static/btn/sm-share-en.gif", "http://www.addthis.com/bookmark.php?v=250", "http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Unchecked.gif"], "published": "2015-10-05T03:00:00.000+03:00", "crawled": "2015-10-07T09:37:58.694+03:00", "highlightTitle": ""}